NCT06888089

Brief Summary

This study aims to evaluate the effectiveness of proactive notifications to treating oncologist to optimize participant accrual to clinical trials by utilizing the MatchMiner AI platform. This study compares the standard MatchMinder AI access method to two enhanced recruitment methods.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20,707

participants targeted

Target at P75+ for not_applicable cancer

Timeline
Completed

Started Jan 2023

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 30, 2023

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 15, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 15, 2024

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

March 11, 2025

Completed
10 days until next milestone

First Posted

Study publicly available on registry

March 21, 2025

Completed
Last Updated

March 21, 2025

Status Verified

March 1, 2025

Enrollment Period

1.5 years

First QC Date

March 11, 2025

Last Update Submit

March 14, 2025

Conditions

Cancer

Keywords

Cancer

Outcome Measures

Primary Outcomes (1)

  • Percentage of Patients Enrolling in Any Dana-Farber Cancer Institute Therapeutic Clinical Trial of Anti-Cancer Systemic Therapy

    This measure assesses the proportion of patients in each study arm who enroll in any Dana-Farber Cancer Institute (DFCI) therapeutic clinical trial involving anti-cancer systemic therapy during the intervention period. Trial enrollment data will be pulled from the institutional OnCore database.

    Up to 18 months

Secondary Outcomes (6)

  • Number of Patients Having Consultations with the Center for Cancer Therapeutic Innovation (CCTI)

    Up to 18 months

  • Percentage of Patients Consenting to Any Clinical Trial of an Anti-Cancer Systemic Therpay

    Up to 18 months

  • Percentage of Patients Predicted to Change Treatment Who Enroll in Any Therapeutic Clinical Trial

    Up to 18 months

  • Percentage of New Systemic Therapy Initiations That Are Clinical Trials of Anti-Cancer Systemic Therapies

    Up to 18 months

  • Clinician Opt-Out Rate from Ongoing Email Notifications

    Up to 18 months

  • +1 more secondary outcomes

Study Arms (3)

Group 1: MatchMiner

NO INTERVENTION

Treating oncologists and investigators can use the standard method of accessing the MatchMiner tool to identify potential clinical trials for eligible participants based on structured genomic criteria.

Group 2: MatchMiner Proactive Notification based on AI-detected progression

EXPERIMENTAL

treating oncologists will automatically receive emails with lists of potential genomically matched clinical trials identified by MarchMiner for patients in whom our AI algorithm detects an elevated probability of changing treatment based on imaging reports; oncologists can also still use traditional MatchMiner workflows.

Other: AI-assisted MatchMiner Platform

MatchMiner AI with Proactive Notification Based on AI-detected progression + Study Team Confirmation

EXPERIMENTAL

treating oncologists will receive email lists of genomically matched clinical trials identified by MatchMiner for patients with AI-detected elevated probability of treatment change, after additional manual review to confirm that patients had progressive diseased based on their imaging reports and did not meet one of the common exclusion criteria for most cancer trials (including uncontrolled brain metastases, multiple primary cancers, poor performance status, lack of measurable disease, already having changed treatment, and hospice enrollment)

Other: AI-assisted MatchMiner Platform

Interventions

AI-assisted MatchMiner PlatformOTHER

A medical record data analysis tool that uses conjunction machine learning and natural language processing models to predict changes in treatment and prognosis and ascertain progression of disease and metastatic sites using retrospective imaging reports. MatchMiner is an established clinical operations tool at Dana-Farber Cancer Institute that links OncoPanel next-generation sequencing data to basic clinical information and clinical trial eligibility criteria to suggest biomarker-selected therapeutic trials for participants.

Group 2: MatchMiner Proactive Notification based on AI-detected progressionMatchMiner AI with Proactive Notification Based on AI-detected progression + Study Team Confirmation

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ≥ 18 years of age
  • adults with any type of cancer whose tumors underwent OncoPanel genomic sequencing from 2013-2022

You may not qualify if:

  • ≤ 18 years of age.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States

Location

Related Publications (1)

  • Mazor T, Farhat KS, Trukhanov P, Lindsay J, Galvin M, Mallaber E, Paul MA, Hassett MJ, Schrag D, Cerami E, Kehl KL. Clinical Trial Notifications Triggered by Artificial Intelligence-Detected Cancer Progression: A Randomized Trial. JAMA Netw Open. 2025 Apr 1;8(4):e252013. doi: 10.1001/jamanetworkopen.2025.2013.

    PMID: 40257799DERIVED

MeSH Terms

Conditions

Neoplasms

Study Officials

  • Kenneth Kehl, MD, MPH

    Dana-Farber Cancer Institute

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

March 11, 2025

First Posted

March 21, 2025

Study Start

January 30, 2023

Primary Completion

July 15, 2024

Study Completion

July 15, 2024

Last Updated

March 21, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will share

The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: Dr. Kehl. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Shared Documents
STUDY PROTOCOL, SAP
Time Frame
Data can be shared no earlier than 1 year following the date of publication
Access Criteria
Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu
More information

Locations

US(1)